Epidemiological and clinical features of idiopathic pulmonary alveolar proteinosis in Japan
- 12 January 2006
- journal article
- Published by Wiley in Respirology
- Vol. 11 (s1) , S55-S60
- https://doi.org/10.1111/j.1440-1843.2006.00810.x
Abstract
Idiopathic pulmonary alveolar proteinosis (IPAP) is a rare disease characterized by excessive amounts of lipoproteinaceous material in the alveolus. This report presents an interim analysis of nationwide epidemiological data from Japanese patients with pulmonary alveolar proteinosis, and the roles of serum markers for IPAP. (i) The nationwide demographic data from 166 Japanese patients with IPAP are shown. The female to male ratio was 1:2, and the average age was 51 +/- 14 years old (age range: 15-79 years) at registration or diagnosis. A total of 30% of patients with IPAP have a poor clinical course. In total, 30% of patients were treated with whole lung lavage therapy (WLL). Under WLL, the patients significantly improved in the short term, but 40% of the patients who underwent WLL worsened again. A new strategy such as granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for intractable PAP is required. (ii) The correlation of serum KL-6, carcinoembryonic antigen, surfactant proteins D and A, and LDH with disease severity suggests their potential as disease markers. In contrast, serum anti-GM-CSF antibody did not correlate with disease severity, but is a specific marker for the diagnosis of IPAP. The combined measurements of the serum markers may well prove very useful for both the diagnosis and the management of IPAP patients.Keywords
This publication has 32 references indexed in Scilit:
- Elevated monocyte chemotactic proteins 1, 2, and 3 in pulmonary alveolar proteinosis are associated with chemokine receptor suppressionClinical Immunology, 2005
- Pulmonary alveolar proteinosisClinics in Chest Medicine, 2004
- Pulmonary Alveolar ProteinosisNew England Journal of Medicine, 2003
- Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosisThorax, 2003
- Rare diseases bullet 6: Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesisThorax, 2000
- Adenovirus-Mediated Granulocyte-Macrophage Colony-Stimulating Factor Improves Lung Pathology of Pulmonary Alveolar Proteinosis in Granulocyte-Macrophage Colony-Stimulating Factor-Deficient MiceHuman Gene Therapy, 1998
- Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression.Journal of Clinical Investigation, 1997
- Efficacy of Granulocyte–Macrophage Colony-Stimulating Factor in Acquired Alveolar ProteinosisNew England Journal of Medicine, 1996
- Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice.Journal of Clinical Investigation, 1996
- Increased Carcinoembryonic Antigen Concentrations in Sera and Bronchoalveolar Lavage Fluids of Patients with Pulmonary Alveolar ProteinosisRespiration, 1995